Literature DB >> 25633465

Serum-derived bovine immunoglobulin/protein isolate should be considered in patients with HIV gut barrier dysfunction.

M S Gelfand1, B P Burnett.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25633465     DOI： 10.1007/s15010-015-0732-7

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  4 in total

1.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

Authors:  Peter W Hunt; Elizabeth Sinclair; Benigno Rodriguez; Carey Shive; Brian Clagett; Nicholas Funderburg; Janet Robinson; Yong Huang; Lorrie Epling; Jeffrey N Martin; Steven G Deeks; Curtis L Meinert; Mark L Van Natta; Douglas A Jabs; Michael M Lederman
Journal:  J Infect Dis       Date:  2014-04-21       Impact factor: 5.226

Review 2.  Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies.

Authors:  S F Assimakopoulos; D Dimitropoulou; M Marangos; C A Gogos
Journal:  Infection       Date:  2014-07-29       Impact factor: 3.553

Review 3.  Serum-derived bovine immunoglobulin/protein isolate: postulated mechanism of action for management of enteropathy.

Authors:  Bryon W Petschow; Bruce Burnett; Audrey L Shaw; Eric M Weaver; Gerald L Klein
Journal:  Clin Exp Gastroenterol       Date:  2014-05-24

4.  Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy.

Authors:  David M Asmuth; Zhong-Min Ma; Anthony Albanese; Netanya G Sandler; Sridevi Devaraj; Thomas H Knight; Neil M Flynn; Tammy Yotter; Juan-Carlos Garcia; Emily Tsuchida; Tsung-Teh Wu; Daniel C Douek; Christopher J Miller
Journal:  AIDS       Date:  2013-09-10       Impact factor: 4.177
  4 in total
  1 in total

1.  On the search for novel treatment modalities for HIV-associated intestinal barrier dysfunction.

Authors:  Stelios F Assimakopoulos; Dimitra Dimitropoulou; Markos Marangos; Charalambos A Gogos
Journal:  Infection       Date:  2015-01-27       Impact factor: 3.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.